Liraglutide pierdere în greutate pcos

Participants with diabetes will be excluded - Willing to use effective contraception consistently during therapy which is defined as: - an intrauterine device, tubal sterilization, or male partner vasectomy, or - combination of two barrier methods with one being male condom.

Abdominal adiposity waist circumference [WC] [Baseline to week 30] Treatment effect on loss of abdominal adiposity 4.

Central adiposity waist-to height ratio [WHtR] [Baseline to week 30] Treatment effect on loss of central adiposity 5. Menstruation frequency [Baseline to week 30] Treatment impact on normalization of cycle frequency 9. Change in glycemic responses from a glucose challenge [Baseline to week 30] Treatment effect on fasting and 2 hour glucose during an oral glucose tolerance test OGTT Surrogate measures of insulin sensitivity [Baseline to week 30] Treatment effect on insulin sensitivity indices determined from fasting and OGTT measures Pancreatic beta cell compensatory function measures [Baseline to week 30] Treatment effect on improving first phase insulin secretion Oral disposition insulin secretion-sensitivity index [Baseline to week 30] Treatment effect on improving insulin action modeled from a 2 hour OGTT Systolic and diastolic blood pressure BP [Baseline to week 30] Treatment impact on reducing blood pressure Alte măsuri de rezultat 1.

Safety laboratory measures creatinine liraglutide pierdere în greutate pcos estimated glomerular filtration rate [eGFR] [Baseline to week 30] Determine if treatment has any adverse impact on renal function as evaluated by blood levels of creatinine and estimated creatinine clearance eGFR 2.

Safety laboratory measures aspartate transaminase [AST levels [Baseline to week 30] Determine if treatment has any adverse impact on liver function as evaluated by AST enzyme concentration 3.

Safety laboratory measures alanine transaminase [ALT] levels [Baseline to week 30] Determine if treatment has any adverse impact on liver function as evaluated by ALT enzyme concentrations 4.

Pregnancy tests laboratory measures and home tests [Baseline to week 30] Confirm patients are not pregnant while under treatment.